BDH Industries Limited

BDH Industries Limited, established in 1935 as Bombay Drug House, is a prominent Indian pharmaceutical company headquartered in Mumbai, Maharashtra. In 1990, it transitioned from a private to a public limited company, adopting the name BDH Industries Limited. The company is registered under the Corporate Identification Number (CIN) L24100MH1990PLC059299. As of the latest available data, BDH Industries has an authorized share capital of ₹75 million and a paid-up capital of ₹57.573 million.

BDH Industries specializes in the manufacture and export of therapeutic formulations, encompassing a wide range of pharmaceutical products. The company operates through two primary segments: Pharmaceuticals and Renewable Energy. In the Pharmaceuticals segment, BDH Industries offers a diverse portfolio, including analgesics, antacids, antibiotics, antifungals, and more. The Renewable Energy segment involves the operation of wind turbines, reflecting the company's commitment to sustainable practices.

BDH Industries' manufacturing facility spans 42,500 square feet and is located in Mumbai, Maharashtra. The plant is accredited with WHO-GMP and ISO 9001:2015 standards, ensuring adherence to stringent quality and compliance protocols. The facility comprises specialized divisions, including Oncology, General Pharmaceuticals (non-sterile and sterile products), and Specialty Products. Manufacturing operations are conducted in strict accordance with Good Manufacturing Practices (GMP), with rigorous process controls and testing standards implemented at each stage of production.

The leadership team at BDH Industries Limited is headed by Ms. Jayashree Nair, who serves as the Chairperson and Managing Director. With over six decades of experience in the pharmaceutical industry, Ms. Nair has been instrumental in the company's growth and global recognition. Mr. S.C. Kachhara holds the position of Managing Director and Chief Financial Officer, bringing over 47 years of experience in the pharmaceutical sector. He has been associated with BDH Industries since 1978 and has played a pivotal role in the company's expansion and financial management. Ms. Karthika Nair serves as a Non-Executive Director, contributing her expertise in genetics and marketing to the company's strategic direction.

BDH Industries Limited has established a significant presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has successfully registered its products with respective drug administrations in these regions, demonstrating compliance with stringent regulatory standards. This global footprint underscores BDH Industries' commitment to providing high-quality pharmaceutical products worldwide.

BDH Industries has expanded its reach into emerging markets across Africa, Latin America, and Southeast Asia. The company's adherence to WHO-GMP standards has facilitated access to these regions, enabling the export of its products to over 30 countries across four continents. This strategic expansion reflects BDH Industries' dedication to addressing global healthcare needs and enhancing its international presence.

BDH Industries Limited has strategically diversified its geographic presence to mitigate concentration risks and capitalize on growth opportunities. By exporting to over 30 countries across four continents, the company has reduced dependency on any single market, thereby enhancing its resilience against regional economic fluctuations. This diversified approach aligns with BDH Industries' strategic direction to establish a robust global footprint in the pharmaceutical industry.

BDH Industries Limited has registered its manufacturing facility with the U.S. Food and Drug Administration (FDA), ensuring compliance with U.S. regulatory standards. The company has also filed Abbreviated New Drug Applications (ANDAs) for its products, facilitating market access in the United States. While specific details regarding Drug Master File (DMF) filings and inspection history are not publicly disclosed, BDH Industries' adherence to WHO-GMP standards indicates a commitment to maintaining high-quality manufacturing practices.

BDH Industries Limited holds WHO-GMP certification, reflecting its compliance with international manufacturing standards. This certification is crucial for exporting pharmaceutical products to various global markets, including the European Union. While specific details regarding EU GMP certificates and EDQM status are not publicly available, the WHO-GMP certification underscores BDH Industries' commitment to quality and regulatory compliance.

In India, BDH Industries Limited operates under the regulatory oversight of the Central Drugs Standard Control Organisation (CDSCO). The company holds manufacturing licenses issued by CDSCO, authorizing the production of pharmaceutical formulations. Additionally, BDH Industries has obtained necessary approvals from state drug controllers and export No Objection Certificates (NOCs), facilitating the export of its products to various international markets.

As of the latest available information, there are no publicly disclosed Form 483 observations, warning letters, or import alerts associated with BDH Industries Limited. The company's adherence to WHO-GMP standards and its commitment to quality manufacturing practices suggest a proactive approach to regulatory compliance.

BDH Industries Limited operates in a competitive pharmaceutical market, with several key players in overlapping therapeutic categories. While specific market share comparisons are not publicly available, BDH Industries' diverse product portfolio and global export reach position it as a significant competitor in the industry. The company's focus on quality manufacturing and regulatory compliance further enhances its competitive standing.

BDH Industries Limited distinguishes itself through its long-standing history in the pharmaceutical industry, spanning over eight decades. The company's commitment to quality is evident in its adherence to WHO-GMP and ISO 9001:2015 standards. Additionally, BDH Industries' diverse product portfolio, encompassing various therapeutic categories, and its global export reach to over 30 countries, underscore its competitive advantages.

BDH Industries Limited's current strategic direction focuses on expanding its global footprint through exports and contract manufacturing partnerships. The company's adherence to international quality standards and its diverse product portfolio position it well for future growth. BDH Industries' commitment to quality and customer satisfaction suggests a strategic focus on maintaining and enhancing its position in the global pharmaceutical market.

BDH Industries Limited has a commendable track record in the pharmaceutical industry, with over 80 years of experience in manufacturing therapeutic formulations. The company's export volume and consistency are evidenced by its active presence in over 30 countries across four continents. Reliability indicators include its adherence to WHO-GMP and ISO 9001:2015 standards, reflecting a commitment to quality and compliance.

Importers should verify the following certifications to ensure product quality and regulatory compliance:

• FDA Registration: Confirm the manufacturer's registration with the U.S. Food and Drug Administration.

• WHO-GMP Certification: Ensure the manufacturer holds a valid WHO-GMP certificate, indicating compliance with international manufacturing standards.

• EU GMP Certification: Verify the manufacturer's EU GMP certificate, confirming adherence to European manufacturing standards.

• ISO 9001:2015 Certification: Check for ISO 9001:2015 certification, reflecting a commitment to quality management systems.

These certifications can typically be verified through the manufacturer's official website or by contacting the relevant regulatory bodies.

When considering BDH Industries Limited as a supplier, importers should undertake the following verification steps:

• Regulatory Compliance: Confirm the validity of FDA, WHO-GMP, EU GMP, and ISO 9001:2015 certifications.

• Product Quality: Request recent quality control reports and batch records to assess product consistency.

• Financial Stability: Review the company's financial statements to evaluate economic health.

• Supply Chain Reliability: Assess the company's logistics capabilities and delivery timelines.

Red flags to watch for include expired certifications, inconsistent product quality reports, and financial instability. Recommended pre-order checks involve obtaining samples for quality assessment and verifying the manufacturer's compliance with international standards.